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Abstract
Acute Lung Injury (ALI) is a syndrome with high associated mortality characterized by severe hypoxemia and pulmonary
infiltrates in patients with critical illness. We conducted the first investigation to use the genome wide association (GWA)
approach to identify putative risk variants for ALI. Genome wide genotyping was performed using the Illumina Human Quad
610 BeadChip. We performed a two-stage GWA study followed by a third stage of functional characterization. In the
discovery phase (Phase 1), we compared 600 European American trauma-associated ALI cases with 2266 European
American population-based controls. We carried forward the top 1% of single nucleotide polymorphisms (SNPs) at p,0.01
to a replication phase (Phase 2) comprised of a nested case-control design sample of 212 trauma-associated ALI cases and
283 at-risk trauma non-ALI controls from ongoing cohort studies. SNPs that replicated at the 0.05 level in Phase 2 were
subject to functional validation (Phase 3) using expression quantitative trait loci (eQTL) analyses in stimulated B-
lymphoblastoid cell lines (B-LCL) in family trios. 159 SNPs from the discovery phase replicated in Phase 2, including loci with
prior evidence for a role in ALI pathogenesis. Functional evaluation of these replicated SNPs revealed rs471931 on 11q13.3
to exert a cis-regulatory effect on mRNA expression in the PPFIA1 gene (p=0.0021). PPFIA1 encodes liprin alpha, a protein
involved in cell adhesion, integrin expression, and cell-matrix interactions. This study supports the feasibility of future multi-
center GWA investigations of ALI risk, and identifies PPFIA1 as a potential functional candidate ALI risk gene for future
research.
Citation: Christie JD, Wurfel MM, Feng R, O’Keefe GE, Bradfield J, et al. (2012) Genome Wide Association Identifies PPFIA1 as a Candidate Gene for Acute Lung
Injury Risk Following Major Trauma. PLoS ONE 7(1): e28268. doi:10.1371/journal.pone.0028268
Editor: William Checkley, Johns Hopkins University, United States of America
Received December 13, 2010; Accepted November 4, 2011; Published January 25, 2012
Copyright:  2012 Christie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the following NIH grants: P50HL60290, P01HL079063, HL081332, HL060710. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jchristi@mail.med.upenn.edu
. These authors contributed equally to this work.
Introduction
Acute lung injury (ALI) is a syndrome characterized by diffuse
pulmonary edema and severe hypoxemia in the absence of clinical
evidence of left atrial hypertension [1]. ALI affects an estimated
190,000 people annually in the United States and carries a
mortality of over 35% [2]. Because only a proportion of patients
exposed to predisposing conditions develop ALI (e.g. following
sepsis, pneumonia, aspiration, or trauma), it has been hypothe-
sized that individual genetic variation may contribute to the
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e28268observed variability in ALI susceptibility [3,4]. Prior studies of
genetics of ALI using candidate gene approaches have identified
variation in genes controlling inflammation, apoptosis, oxidative
stress, or endothelial permeability among others that may confer
differential risk of developing ALI [5,6,7,8,9,10,11,12,13,14,15].
adding to evidence that risk of developing ALI may have a genetic
basis.
Genome-wide association studies (GWAS) are powerful,
unbiased tools for the identification of common genetic variants,
e.g., single nucleotide polymorphisms (SNPs), associated with
complex traits [16]. Despite potential limitations [17], GWAS
have led to the identification of genetic susceptibility loci that
reproducibly confer risk for complex diseases such as Crohn’s
disease, rheumatoid arthritis, and Type II diabetes [16,18,19]. To
date, the GWAS approach has not been applied to the study of
ALI.
We report the first GWAS of ALI susceptibility, using a three
stage approach, including a discovery phase, a replication phase,
and a functional evaluation phase using gene expression screening
in family trios. We hypothesized that a GWAS approach would
identify common genetic variants associated with a reproducible
differential risk of ALI.
Methods
This study was approved by the institutional review boards
(IRBs) of the Children’s Hospital of Philadelphia (CHOP), the
University of Pennsylvania School of Medicine, University of
Washington, Harvard School of Public Health, Vanderbilt
University, and the University of California at San Francisco.
Study Populations
We chose an at-risk trauma population to minimize heteroge-
neity from multiple precipitating factors of ALI and to efficiently
allow for comparison with population-based controls, as major
trauma is largely a stochastic event across populations. ALI cases
and at-risk controls were identified from severe trauma cohort
studies performed at 5 U.S. centers: Harvard University/
Massachusetts General Hospital, University of Pennsylvania,
Vanderbilt University, University of Washington, and University
of California at San Francisco. Entry criteria were an Injury
Severity Score (ISS) $16 and admission through the Emergency
department to an intensive care unit. ALI was defined accord-
ing to American European Consensus Conference (AECC)
criteria [20] by trained investigators at each site [13,14,21,
22,23,24,25,26]. Written informed consent was obtained from
participants at Harvard University/Massachusetts General Hos-
pital, Vanderbilt University, University of Washington, and
University of California at San Francisco. Participants at
University of Pennsylvania were collected under a waiver of
consent granted by the University of Pennsylvania IRB.
Population-based controls were recruited from ongoing cohorts
at the Center for Applied Genomics at CHOP [27,28].
Study Design
We performed a two-stage genotyping strategy [29], with a third
stage of functional characterization (Figure 1). In the discovery
phase (Phase 1), we compared 600 European American trauma-
associated ALI cases with 2266 European American population-
based pediatric healthy controls taken from ongoing studies at
Children’s Hospital of Philadelphia (CHOP). Pediatric population
controls [27,28] were chosen for the discovery phase to maximize
efficiency and cost savings [30] for the following reasons: these
controls were available in large number and had been genotyped
on the same genome-wide platform during a similar time; ALI is
not a chronic disease, there is no known effect of cumulative life
exposures on ALI risk following trauma; a major environmental
insult (trauma) is required to become at risk for ALI; and a recently
published study by our group found little difference between these
pediatric population controls and other adult controls [31].
We carried forward SNPs with p,0.01 for ALI association in
our discovery sample to a replication phase (Phase 2) [29]. The
replication population consisted of a nested case-control design of
212 ALI cases and 283 at-risk major trauma controls from ongoing
cohort studies at the five participating centers. At-risk controls
were defined as severely injured subjects with ISS.16 [32],
admitted to the intensive care unit who did not develop ALI
during hospital stay, and were primarily drawn from two sites
(HSPH and UW). We used logistic regression to adjust for
potential confounding clinical factors, including age, ISS, and
mechanism of trauma (classified as blunt or penetrating).
SNPs that achieved significance at p,0.05 level in our Phase 2
replication set were subject to functional evaluation using
expression quantitative trait loci (eQTL) analyses for cis-regulating
elements from B-LCL derived from 60 European ancestry and
Yoruban HapMap trios (mother, father, offspring) evaluated under
two conditions: stimulated with CL097, an innate immune agonist
acting through Toll-like receptor 7 (TLR7), or with culture media
alone [33]. Cis-acting eQTL in the setting of CL097-exposed B-
LCL were determined using a linear regression model in unrelated
individuals. Cis-tests were performed with SNPs (allele frequen-
cy.5%) mapping within 1 MB of the array probe start site. Cis
eQTL were confirmed in the parent-offspring trios using the
quantitative transmission-disequilibrium test (QTDT) [34], as
implemented in the QTDT software package (http://www.sph.
umich.edu/csg/abecasis/QTDT/index.html).
Genotyping Methods and Quality Control
We used the Illumina HumanQuad610 BeadChip (Illumina,
San Diego) to determine genotypes for 620,901 linkage disequi-
librium bin-tagging polymorphisms and copy number variation
(CNV) markers. Approximately 500 ng of genomic DNA from
peripheral blood samples was used for each subject. Each sample
was whole-genome amplified, fragmented, precipitated, and
Figure 1. Overview of study design. Abbreviations: ALI, acute lung
injury; eQTL, eQTL, expression quantitative trait loci.
doi:10.1371/journal.pone.0028268.g001
GWAS Identifies PPFIA1 as Candidate ALI Risk Gene
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e28268resuspended in hybridization buffer. Denatured samples were next
hybridized on BeadChips for 16 hours at 48uC, the single base
extension reaction performed, and the chip stained and imaged on
an Illumina Bead Array Reader. Normalized intensity data for
each sample were loaded into Illumina Beadstudio 2.0 and
genotypes called using the manufacturer’s clustering algorithm.
Gender was checked using built-in controls. Clusters were checked
for separation, deviation from Hardy-Weinberg, and lack of
variation (mono-morphism). Genotypes that did not deviate from
Hardy-Weinberg Equilibrium, demonstrated .95% call rate, and
a minimum quality score determined by the manufacturer’s
software, were eligible for statistical association analyses. SNP
imputation was also performed on the discovery cohort using the
Markov Chain Haplotyping (MACH) software (http://www.sph.
umich.edu/csg/abecasis/MaCH/index.html) for genotype impu-
tation on markers that are not present in the genotyping platform
used. The software version 1.0.16 was used in the study, and the
default two-step procedure was adopted for imputation. The
software requires several input files for SNPs and phased
haplotypes, so we used the HapMap phased haplotypes (release
22) on HapMap Utah residents with ancestry from northern and
western Europe (CEU) subjects, as downloaded from the HapMap
database (http://www.hapmap.org). We analyzed the mlinfo file
generated from the imputation process and used the recom-
mended R
2 threshold of 0.3 to flag unreliable markers used in
imputation analysis, and removed these markers from association
tests. We also analyzed the mlqc file, which provides a per-
genotype posterior probability for each imputed call, and we used
the 0.9 threshold to flag unreliable calls (by recoding them as
NoCall genotype). In total, 2,487,415 imputed autosomal markers
(out of 2.54 million markers with phase information in HapMap
CEU population) passed quality control for the ALI cohort. We
have included all loci with p,0.01 in Phase 1 in Supplemental
Table S2.
Statistical Analysis
Statistical tests for genetic association were conducted using
PLINK [35]. To reduce the risk of population stratification due to
misspecification of self-reported ancestry, we screened all cases and
controls at ancestry informative markers (AIMs) using the
STRUCTURE software package and removed outliers from
principal components analysis. Using the methods of Skol [36] and
assuming an additive model, two-stage design, 800 cases, 2500
controls, and carrying forward SNPs with an association p,0.01
in an additive model to stage 2 with a replication alpha of 0.05,
we determined that we would have greater than 80% power for
both Stage 1 and replication analyses to detect a relative risk of
1.5 or greater for allele frequencies of 0.10 or greater. Power for
SNP detection in individual phases was less. Phase 1 with 600
cases and 2200 controls yielded greater than 80% power for a
detectable relative risk of 1.5 or greater at an alpha of 0.01 for
allele frequencies greater than 0.10 (detectable RR 1.9 for
p,5610
28). In Phase 2 we had 80% power to detect relative
risks of 1.8 or greater at alpha 0.05 for allele frequencies of
greater than 0.10.
Results
Sample flow of ALI cases is presented in Supplemental Figure
S1. Characteristics of the ALI case, population control, and at-risk
control populations are contained in Table 1. In Phase 1, the
mean age of the ALI cases was 45 years, 70% were male, 92% had
blunt trauma and the mean ISS was 27. The mean age of the
controls was 9 years and 57% were male. In Phase 2, age, gender,
ISS, and mechanism of trauma were similar between cases and
controls. Supplemental Table S1 presents subject characteristics
by site. Age, gender, and ISS were similar according to individual
sites within cases and controls.
Following QC and filtering, the genomic inflation factor for the
Phase 1 discovery set was 1.027, indicating minimal differences in
underlying population structure between cases and controls
(Figure 2). Figure 3 represents a Manhattan plot of 2log10(p-
value) in the Phase 1 discovery cohort. A total of 5815 genotyped
SNPs demonstrated association in the Phase 1 discovery cohort at
p,0.01; these SNPs were carried forward to the replication phase
(Phase 2). Supplemental Table S2 presents results of 28,618
imputed SNPs from Phase 1 that were associated with ALI at
p,0.01.
A total of 159 SNPs achieved p,0.05 in the Phase 2
replication set with similar direction of OR when adjusted for
age, gender, ISS, and mechanism of trauma (Supplemental Table
S3). Of note, several of these SNPS were in genes that could
plausibly be associated with mechanisms contributing to ALI
(Table 2), including members of the thrombospondin [37,38],
tetraspanin [39], and chitinase families [40,41]. One replicated
variant resulted in an amino acid substitution in the correspond-
ing gene product, a Leu29Ile substitution in CCL24 (or eotaxin-
2) [42].
Table 1. Demographics of Trauma ALI SNP Consortium (TASC) subjects.
Phase 1 (n=2866) Phase 2 (n=495)
Cases (n=600) Controls (n=2266) Cases (n=212) Controls (n=283)
Gender n=596
Males (%) 419 (70%) 1287 (57%) 158 (75%) 206 (73%)
Female (%) 177 (30%) 979 (43%) 54 (25%) 77 (27%)
Age in years n=589 n=2250 n=195 n=270
44.78 (620.05) 8.64 (65.72) 44.32 (619.66) 38.90 (620.76)
ISS n=542 n=194 n=266
26.97 (69.98) NA 27.77 (610.44) 23.94 (610.72)
Blunt Injury (%) n=528 n=180 n=173
488 (92%) NA 168 (93%) 149 (86%)
Abbreviations: ALI, acute lung injury; SNP, single nucleotide polymorphism; ISS, Injury Severity Score; NA, not applicable.
doi:10.1371/journal.pone.0028268.t001
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forward to functional evaluation in Phase 3. In eQTL analyses of
TLR-7 stimulated HAPMAP B-LCL, there was significant
differential expression of PPFIA1 mRNA (p=0.0021) according
to genotype of rs471931, a cis-acting SNP on 11q13.3 (Table 3).
The PPFIA1 gene encodes liprin alpha, a protein involved in cell
adhesion and cell-matrix interactions [43].
We additionally screened our discovery phase to test the
association of loci with prior reported association with ALI
(Table 4). Notably, the IL10 SNP (rs1800896 at 21082 in the
promoter region) showed a similar effect on ALI risk as in prior
reports [12]. However, as our GWA platform was not specifically
designed to provide adequate coverage for these loci of interest,
many of the previously associated SNPs in other genes were not
available. Therefore, we also report results for other SNPs within
the same candidate genes in Table 4. Several of these candidate
genes contained additional loci associated with ALI risk including
IL10, FAS [44], MYLK [45], and ANGTP2, although the specific
SNPs from prior publications did not replicate in the case of FAS
and MYLK.
Discussion
To our knowledge, this is the first genome wide association
study to examine the risk of ALI. We demonstrate association at
multiple loci in two independent datasets; when coupled to eQTL
analysis, the putatively functional results prioritize novel loci for
future ALI research. Furthermore, this study provides evidence of
feasibility for future GWAS in trauma and other at-risk
populations, including those using at-risk controls in the discovery
phase.
The putatively functional genetic variant identified in this study
suggests a compelling hypothesis to explain the pathogenesis of the
observed link with ALI risk. The protein encoded by the PPFIA1
gene is a member of the liprin (LAR protein-tyrosine phosphatase-
interacting protein) family [46]. Liprins have mostly been studied
in the nervous system and in mammary gland development [46];
however, liprin alpha binds to the intracellular membrane-distal
phosphatase domain of tyrosine phosphatase ‘leukocyte antigen
related’’ (LAR), and may regulate the disassembly of focal cell
adhesion, influencing cell-matrix interactions [47]. Liprin alpha
Figure 2. Quantile-Quantile (Q-Q) plot of single SNP association with ALI.
doi:10.1371/journal.pone.0028268.g002
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beta1 integrins [48]. Integrins are involved in the pathogenesis
ALI through interactions with the extracellular matrix, altering
cell adhesion and lung vascular permeability [49,50].
The exact function of the genetic regulation of rs471931 on the
PPFIA1 gene is not known. It is approximately 280Kb downstream
of PPFIA1 on 11q13.3 and there are intervening genes, including
SHANK2. Future studies may focus on fine mapping the region to
better understand the role of genetic regulation of liprin alpha
expression in ALI risk.
A novel feature of our study is the use of eQTL analyses that
employ transformed stimulated lymphocytic cell lines to evaluate
functional differences between the genotypes on our list, providing
evidence of differential expression according to our ALI-risk
Figure 3. Manhattan plot of 2log10(p-value) for SNP association with ALI.
doi:10.1371/journal.pone.0028268.g003
Table 2. Replicated SNPS with putative functional roles in ALI pathogenesis.
Chr SNP
Disc.
OR
Disc.
p
Risk
allele
MAF
ALI
MAF
contrl
Repl.
OR
Repl.
p Symbol Gene Name
Entrez
gene ID
5 rs2398611 0.65 0.0012 C 0.05 0.10 0.47 0.0061 ARHGAP26 Rho GTPase activating protein 26 23092
12 rs1468674 1.25 0.0014 G 0.53 0.46 1.33 0.0386 KLRB1 killer cell lectin-like receptor subfamily B, member 1 3820
5 rs248244 1.60 0.0015 T 0.08 0.05 1.83 0.0347 SQSTM1 sequestosome 1 8878
21 rs2838659 0.78 0.0032 G 0.21 0.25 0.70 0.0330 TSPEAR thrombospondin-type laminin G domain and EAR
repeats
54084
1 rs1321106 1.23 0.0036 C 0.37 0.31 1.41 0.0193 TSPAN2 tetraspanin 2 10100
12 rs2701129 0.69 0.0045 A 0.09 0.13 0.57 0.0179 NR4A1 nuclear receptor subfamily 4, group A, member 1 3164
14 rs847301 0.63 0.0051 T 0.03 0.07 0.47 0.0298 RGS6 regulator of G-protein signaling 6 9628
5 rs4546368 0.82 0.0053 T 0.41 0.47 0.75 0.0371 ABLIM3 actin binding LIM protein family, member 3 22885
7 rs7778918 0.81 0.0055 A 0.30 0.35 0.73 0.0498 THSD7A thrombospondin, type I, domain containing 7A 221981
10 rs1948837 1.56 0.0061 G 0.06 0.04 1.89 0.0447 PRKG1 protein kinase, cGMP-dependent, type I 5592
8 rs12547884 0.78 0.0068 A 0.18 0.26 0.66 0.0162 MSRA methionine sulfoxide reductase A 4482
7 rs2302006 0.78 0.0072 A 0.17 0.24 0.70 0.0463 CCL24 chemokine (C-C motif) ligand 24 6369
1 rs3820145 0.78 0.0084 A 0.17 0.23 0.62 0.0104 CHIT1 chitinase 1 1118
10 rs7922288 1.27 0.0086 C 0.20 0.15 1.47 0.0312 PTPRE protein tyrosine phosphatase, receptor type, E 5791
6 rs237012 1.20 0.0091 A 0.53 0.44 1.35 0.0389 TAB2 TGF-beta activated kinase 1/MAP3K7 binding protein 2 23118
10 rs1317790 1.38 0.0098 T 0.12 0.08 1.61 0.0444 MPP7 membrane protein, palmitoylated 7 143098
3 rs4553956 0.81 0.0101 T 0.22 0.28 0.70 0.0271 TP63 tumor protein p63 8626
8 rs8178179 1.42 0.0107 C 0.08 0.04 2.24 0.0110 PRKDC protein kinase, DNA-activated, catalytic polypeptide 5591
15 rs10520676 0.80 0.0101 G 0.18 0.24 0.64 0.0109 NTRK3 neurotrophic tyrosine kinase, receptor, type 3 4916
Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphism; OR, odds ratio; Disc. or, odds ratio from phase 1 additive trend model; Disc. p, p value from
phase 1 additive trend model; maf, minor allele frequency; ali: acute lung injury; repl. or, or from phase 2 additive trend model; repl. p, p value from phase 2 additive
trend model.
doi:10.1371/journal.pone.0028268.t002
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differential expression exists in cell types that were not included
in our approach, such as in pneumocytes or macrophages [18].
Therefore, SNPs not found to have differential expression in our
functional phase could potentially have functional consequences in
other tissues and be linked to ALI risk. However, as of the time of
this publication there were no available datasets with both
genome-wide genotyping and genome-wide gene expression in
lung specific tissues to our knowledge. As such, we have presented
the results of association for the 159 SNPs replicating to nominally
significant p-values in Phase 2, as lack of functional correlation in
our study does not rule out a role in ALI risk.
Of replicated loci, several have hypothesized putative roles in
ALI pathogenesis, as presented in Table 2. In particular, members
of the thrombospondin and chitinase families [40,41] have been
implicated in ALI pathogenesis [37,38]. Tetraspanins have been
shown to influence lipopolysaccharide-induced macrophage acti-
vation and lung inflammation [39]. CD161 has recently been
implicated in regulating the tissue-homing and inflammatory
effects of T-cells, including IL-17 producing cells [51,52,53].
Methionine sulfoxide reductase A (MSRA) protects against
oxidative stress [54], and the TAB2 gene encodes a protein in
the IL-1 signal transduction pathway [55,56]. ARGAP26 encodes
Rho GTPase activating protein 26; and Rho family GTPases may
regulate endothelial barrier integrity through interactions with the
actin cytoskeleton [57]. Likewise, the protein product actin-
binding LIM 3 (abLIM3) has recently been described to affect
barrier integrity in bronchial epithelium through actin binding as a
component of the junctional complex [58].
One of our replicated loci resulted in an amino acid change in
the protein product CCL24. This encoded protein, also known as
eotaxin-2, has been involved in pulmonary allergic response [42],
and there is evidence of alteration of levels due to genetic variation
in humans [59]. Likewise, the potential functional consequence of
the specific IL10 SNP rs1800896 sets this promoter variant as a
priority for future studies of ALI. Of note, in the original
description by Gong, et al, an interaction was detected with
younger age, as is seen in the relatively young age of our trauma
study cohort [12]. In addition, although prior published SNPS did
not replicate, gene-based replication of prior FAS, ANGTP2, and
MYLK associations with ALI prioritize these candidate loci for
future study.
The use of population-based controls in the derivation stage
allowed for optimization of power while preserving at-risk trauma
controls for the replication stage. Although this approach is
efficient and economical, there may have been biases introduced
because the controls did not suffer the same predisposing risk
factor (major trauma), and were drawn from pediatric cohorts.
ALI only develops after a severe precipitating insult, and ALI
susceptibility genes may be quiescent unless a severe environmen-
tal insult occurs (e.g. sepsis, influenza, blood transfusion, or major
trauma) [60]. Therefore, it is possible that there are ALI
susceptibility genes that were not apparent in our discovery phase
(false negative results). Nonetheless, we do not believe our choice
of controls in Phase 1 would lead to false positive results for the
following reasons: a) none of our candidate genes are plausibly
linked with survival to the age of traumatic insult; b) the pediatric
population controls have been shown to be similar to adult
population controls; and c) and Phase 2 used at-risk nested
controls with major trauma that were followed for ALI
determination but did not develop the syndrome, thereby
minimizing selection bias. However, it is likely that a larger
discovery phase using at-risk trauma controls of similar age may
uncover additional risk variants. We estimate that 1000 cases and
at-risk controls would provide adequate power to detect genotype
relative risks greater than 1.6 for common variants, and larger
samples would be needed for uncommon variants.
Our study has several additional limitations. First, the discovery
sample set is on the lower bounds of power for demonstrating
GWAS significance [36,61]. Although we were powered to detect
common SNPs in a two-stage design, our replication sample was
modest; we may have missed important (and less common)
variants and therefore negative findings should be interpreted with
caution [16]. However, our three-stage genotyping approach with
functional characterization of the resulting association signals
should minimize the chances of our findings being false positive
associations. Likewise, for efficiency and economy, our discovery
phase used already-genotyped controls from a single site; therefore
confounding due to population stratification may have been
possible. However, our statistical approach yielded an excellent
genomic inflation factor, and our results replicated in subjects
taken from several sites in Phase 2, making population admixture
unlikely to bias our results. None of our SNPs achieved
significance in our derivation set at the genome-wide multiple
comparison level (p,5610
28). However, this should not be
interpreted as a lack of evidence of a genetic basis for ALI, given
the modest sample size, and given the positive results of our three-
stage study design [27]. We chose the trauma population to
minimize heterogeneity of ALI etiology and efficiently leverage
population-based controls in the Phase 1 discovery phase.
However, the pathophysiology of ALI following trauma may be
different than other at risk ALI populations [62], and therefore the
findings may not be generalizable to other causes of ALI. Future
studies will need to replicate our findings in other at-risk
populations.
As the first GWA in acute lung injury, our study has uncovered
an important novel variant regulating PPFIA1 expression to
prioritize for future studies. Furthermore, our study supports the
feasibility of using a multiple-staged GWAS approach in future
studies of ALI risk. Bench and translational research studies
focused on the roles of liprin alpha 1 in ALI pathogenesis seem
warranted. In addition, we have replicated a candidate gene with
prior ALI association as well as several genes in pathways with
evidence of a role in ALI pathogenesis to serve as priority
candidates for future study. Like other complex syndromes,
additional novel putative risk genes will likely be uncovered with
Table 3. Replicated SNP that alters expression in stimulated B-lymphoblastic cell lines (B-LCLs) [33].
CHR SNP
MAF
ALI/Control Phase 1 OR
Phase 1
P-value
Phase 2
OR
Phase 2
P-value
Expressed
mRNA
Phase 3 eQTL
P-value
11 rs471931 0.50/0.45 1.20 0.0107 1.53 0.0045 PPFIA1 0.0021
Abbreviations: SNP, single nucleotide polymorphisms; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; mRNA, messenger ribonucleic acid; eQTL,
expression quantitative trait loci.
doi:10.1371/journal.pone.0028268.t003
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Gene Chr SNP Reference Candidate SNP Candidate Gene
F5 1 rs6025 (Arg506Gln) [63] N/A NS
IL10 1 rs1800896 (A/G 21082) [64] OR 1.15 p=0.039 rs1554286
OR 0.80
p=0.00498
IL1RN 2 rs4251961 [65] OR 1.02 p=0.80 NS
NFE2L2 2 rs1754059 (C/A 2617) [9] N/A NS
SFTPB 2 rs1130866 (T/C +1580) [66,67,68] OR 1.07 p=0.54 NS
MYLK 3 rs9840993 [6,45] N/A rs11718105
rs4678047 OR 0.93 p=0.33 OR 1.28
rs28497577 N/A p=0.00150
SOD3 4 rs1007991 [7] N/A NS
rs8192291 N/A
rs2695232 N/A
rs2855262 N/A
TLR1 4 rs5743551 (A/G 2720) [69] N/A NS
TNF 6 rs1800629 (G/A 2308) [70] OR 0.88 p=0.48 NS
VEGF 6 rs833061 (C/T 2460) [71,72] OR 1.09 p=0.39 NS
rs2010963 (C/G +405) N/A
rs3025039 (C/T +936) N/A
IL6 7 rs4800795 (G/C 2174) [73,74,75,76] OR 1.06 p=0.46 NS
PBEF1 7 rs41496055 [8] N/A NS
ANGPT2 8 rs2959811 [77,78] OR 0.89 p=0.10 rs7825407
rs2515475 OR1.00 p=0.97 OR 1.27
rs1868554 – imputed OR 1.22 P=0.00189
p=0.0083
FAS 10 rs2147420 - imputed [44] OR 0.99 p=0.86 rs9658691
rs2234978 - typed OR .93 p=0.30 OR 0.68
rs1051070 - imputed OR 1.02 p=0.96 p=0.00102
MBL2 10 rs1800451 [79,80,81] N/A NS
PLAU 10 rs1916341 [82] N/A NS
rs2227562 OR 1.02 p=0.88
rs2227564 OR 0.97 p=0.71
rs2227566 N/A
rs2227571 N/A
rs4065 OR 0.97 p=0.58
IRAK3 12 rs10506481 - imputed [83] OR 0.96 p=0.75 NS
NFKBIA 14 rs3138053 (A/G 2881) [84] OR 0.83 p=0.073 NS
rs2233406 (C/T 2826) N/A
rs2233409 (C/T 2297) N/A
HMOX2 16 rs1362626 [85] OR 0.99 p=0.87 NS
rs2404579 N/A
rs2270366 OR 1.03 p=0.70
rs1051308 OR 1.03 p=0.70
rs7702 OR 0.97 p=0.73
NQO1 16 rs689455 [86] N/A NS
FTL 19 rs905238 [85] OR 1.07 p=0.31 NS
rs918546 N/A
rs2230267 N/A
MIF 22 rs2070767 [87] N/A NS
rs755622 N/A
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Supporting Information
Figure S1 Schematic representation of the quality control
method employed. Of the total 1066 cases of ALI submitted for
analysis, 217 were excluded from further analyses due to evidence
of non-European ancestry. (Abbreviations: ALI, acute lung injury;
AIM, ancestry informative markers; PCA, principal components
analysis; Pre-QC EA pre-quality control; EA’ European-Ameri-
can; GWA, Genome Wide Association).
(TIF)
Table S1 Subjects Characteristics by site. (Abbreviations: ALI,
acute lung injury; SNP, single nucleotide polymorphism; ISS,
Injury Severity Score; NA, not applicable).
(DOCX)
Table S2 Imputed Phase 1 loci with p,0.01 for ALI association.
(Abbreviations: CHR, chromosome; SNP, single nucleotide
polymorphism; BP, base pair location; OR, odds ratio; ANNOT,
annotated locus).
(XLSX)
Table S3 Phase 2 SNPs with p,0.05 and consistent direction of
OR when adjusted for age, gender, injury severity score (ISS), and
mechanism of trauma. (Abbreviations: SNP, single nucleotide
polymorphism; BP, base pair location OR, odds ratio; Discover-
y_or_trend, odds ratio from phase 1 additive trend model;
Discovery_p_trend, p value from phase 1 additive trend model;
maf, minor allele frequency; ali: acute lung injury; replicatio-
n_or_trend, or from phase 2 additive trend model; replication_p_
trend, p value from phase 2 additive trend model; l95_trend, lower
bound of the confidence interval for or from phase 2 additive trend
model; u95_trend, upper bound of the confidence interval for or
from phase 2 additive trend model).
(XLS)
Author Contributions
Conceived and designed the experiments: JDC MMW JB DCC RA HH.
Performed the experiments: JDC JB CK MMW JA RA HH AKM.
Analyzed the data: RF JB NJM JDC ML JA MMW HH. Contributed
reagents/materials/analysis tools: JDC MMW GEO LBW DCC CSC
MJC MM KCB JS PNL AKM RA JPM HH. Wrote the paper: JDC
MMW DCC LBW CSC MM KCB JS JPM RA HH.
References
1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, et al. (1994) The
American-European Consensus Conference on ARDS. Definitions, mecha-
nisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care
Med 149: 818–824.
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, et al. (2005)
Incidence and outcomes of acute lung injury. N Engl J Med 353: 1685–1693.
3. Gong MN (2006) Genetic epidemiology of acute respiratory distress syndrome:
implications for future prevention and treatment. Clin Chest Med 27: 705–724;
abstract x.
4. Barnes KC (2005) Genetic determinants and ethnic disparities in sepsis-
associated acute lung injury. Proc Am Thorac Soc 2: 195–201.
5. Christie JD, Ma SF, Aplenc R, Li M, Lanken PN, et al. (2008) Variation in the
MYLK gene is associated with development of acute lung injury after major
trauma. Crit Care Med.
6. Gao L, Grant A, Halder I, Brower R, Sevransky J, et al. (2006) Novel
polymorphisms in the myosin light chain kinase gene confer risk for acute lung
injury. Am J Respir Cell Mol Biol 34: 487–495.
7. Arcaroli JJ, Hokanson JE, Abraham E, Geraci M, Murphy JR, et al. (2009)
Extracellular superoxide dismutase haplotypes are associated with acute lung
injury and mortality. Am J Respir Crit Care Med 179: 105–112.
8. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, et al. (2005) Pre-B-
cell colony-enhancing factor as a potential novel biomarker in acute lung injury.
Am J Respir Crit Care Med 171: 361–370.
9. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, et al. (2007)
Functional polymorphisms in the transcription factor NRF2 in humans increase
the risk of acute lung injury. FASEB J 21: 2237–2246.
10. Gong MN, Wei Z, Xu LL, Miller DP, Thompson BT, et al. (2004)
Polymorphism in the surfactant protein-B gene, gender, and the risk of direct
pulmonary injury and ARDS. Chest 125: 203–211.
11. Zhai R, Zhou W, Gong MN, Thompson BT, Su L, et al. (2007) Inhibitor
kappaB-alpha haplotype GTC is associated with susceptibility to acute
respiratory distress syndrome in Caucasians.[see comment]. Critical Care
Medicine 35: 893–898.
12. Gong MN, Thompson BT, Williams PL, Zhou W, Wang MZ, et al. (2006)
Interleukin-10 polymorphism in position 21082 and acute respiratory distress
syndrome.[see comment]. European Respiratory Journal 27: 674–681.
1 3 .T e j e r aP ,W a n gZ ,Z h a iR ,S uL ,S h e uC - C ,e ta l .( 2 0 0 9 )G e n e t i c
polymorphisms of peptidase inhibitor 3 (elafin) are associated with acute
respiratory distress syndrome. American Journal of Respiratory Cell &
Molecular Biology 41: 696–704.
14. Su L, Zhai R, Sheu C-C, Gallagher DC, Gong MN, et al. (2009) Genetic
variants in the angiopoietin-2 gene are associated with increased risk of ARDS.
Intensive Care Medicine 35: 1024–1030.
15. Glavan BJ, Holden TD, Goss CH, Black RA, Neff MJ, et al. (2010) Genetic
Variation in the FAS Geneand Associations with Acute Lung Injury.Am JRespir
Crit Care Med;EPub 201003-200351OC.
16. Hardy J, Singleton A (2009) Genomewide association studies and human
disease. New England Journal of Medicine 360: 1759–1768.
17. Visscher PM, Montgomery GW (2009) Genome-wide association studies and
human disease: from trickle to flood. JAMA 302: 2028–2029.
18. Ioannidis JPA, Thomas G, Daly MJ (2009) Validating, augmenting and refining
genome-wide association signals. Nature Reviews Genetics 10: 318–329.
19. Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease.
Science 322: 881–888.
20. Bernard GR, Reines HD, Brigham KL, Carlet J, Flake J, et al. (1994) The
American European consensus conference on ARDS: definitions, mechanisma,
relevant outcomes and clinical trials coordination. Am J Resp Crit Care Med
149: 818–824.
Gene Chr SNP Reference Candidate SNP Candidate Gene
Structural Variants
ACE In/del [88,89,90] N/A NS
NFKB1 In/del promoter [91] N/A NS
PAI1 4G/5G [92] N/A NS
SNP-level results are provided if the specific locus previously reported to associate with ALI was either directly genotyped by the Human 660quad platform or was able
to be imputed with a posterior probability (r
2) 0.90. If no imputation was possible due to SNP rarity or lack of linkage disequilibrium with genotyped markers, the result
is given as ‘‘Not Available’’ (N/A). At the gene level, the strongest association reported for the gene, as annotated by the NCBI RefSeq position, is reported when
associations resulted in a probability p#0.01. If no SNP annotated to the gene was associated with p#0.01, the result is given as ‘‘Not Significant’’ (NS). The results for
ANGPT2 in this population have previously been published [78].
doi:10.1371/journal.pone.0028268.t004
Table 4. Cont.
GWAS Identifies PPFIA1 as Candidate ALI Risk Gene
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e2826821. Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, et al. (2009) Early
release of high mobility group box nuclear protein 1 after severe trauma in
humans: role of injury severity and tissue hypoperfusion. Critical Care (London,
England) 13: R174.
22. Cohen MJ, Carles M, Brohi K, Calfee CS, Rahn P, et al. (2010) Early release of
soluble receptor for advanced glycation endproducts after severe trauma in
humans. Journal of Trauma-Injury Infection & Critical Care 68: 1273–1278.
23. Sheu C-C, Zhai R, Wang Z, Gong MN, Tejera P, et al. (2009) Heme oxygenase-
1 microsatellite polymorphism and haplotypes are associated with the
development of acute respiratory distress syndrome. Intensive Care Medicine
35: 1343–1351.
24. Reddy AJ, Christie JD, Aplenc R, Fuchs B, Lanken PN, et al. (2009) Association
of human NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphism with
development of acute lung injury. Journal of Cellular & Molecular Medicine 13:
1784–1791.
25. Christie JD, Ma S-F, Aplenc R, Li M, Lanken PN, et al. (2008) Variation in the
myosin light chain kinase gene is associated with development of acute lung
injury after major trauma. Critical Care Medicine 36: 2794–2800.
26. Shalhub S, Junker CE, Imahara SD, Mindrinos MN, Dissanaike S, et al. (2009)
Variation in the TLR4 gene influences the risk of organ failure and shock
posttrauma: a cohort study. Journal of Trauma-Injury Infection & Critical Care
66: 115–122; discussion 122-113.
27. Sleiman PMA, Flory J, Imielinski M, Bradfield JP, Annaiah K, et al. (2010)
Variants of DENND1B associated with asthma in children. New England
Journal of Medicine 362: 36–44.
28. Flory JH, Sleiman PM, Christie JD, Annaiah K, Bradfield J, et al. (2009) 17q12–
21 variants interact with smoke exposure as a risk factor for pediatric asthma but
are equally associated with early-onset versus late-onset asthma in North
Americans of European ancestry. Journal of Allergy & Clinical Immunology
124: 605–607.
29. Satagopan JM, Elston RC (2003) Optimal two-stage genotyping in population-
based association studies. Genet Epidemiol 25: 149–157.
30. Luca D, Ringquist S, Klei L, Lee AB, Gieger C, et al. (2008) On the use of
general control samples for genome-wide association studies: genetic matching
highlights causal variants. American Journal of Human Genetics 82: 453–463.
31. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, et al. (2011)
Identification of common variants influencing risk of the tauopathy progressive
supranuclear palsy. Nat Genet 43: 699–705.
32. Civil ID, Schwab CW (1988) The Abbreviated Injury Scale, 1985 Revision: A
Condensed Chart For Clinical Use. The Journal of Trauma 28: 87–90.
33. Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, et al. (2007) Gene-
expression variation within and among human populations.[Erratum appears in
Am J Hum Genet. 2007 Jun;80(6):1194]. American Journal of Human Genetics
80: 502–509.
34. Abecasis GR, Cardon LR, Cookson WO (2000) A general test of association for
quantitative traits in nuclear families. American Journal of Human Genetics 66:
279–292.
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
36. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more
efficient than replication-based analysis for two-stage genome-wide association
studies.[Erratum appears in Nat Genet. 2006 Mar;38(3):390]. Nature Genetics
38: 209–213.
37. Idell S, Maunder R, Fein AM, Switalska HI, Tuszynski GP, et al. (1989) Platelet-
specific alpha-granule proteins and thrombospondin in bronchoalveolar lavage
in the adult respiratory distress syndrome. Chest 96: 1125–1132.
38. Bornstein P (2001) Thrombospondins as matricellular modulators of cell
function. J Clin Invest 107: 929–934.
39. Suzuki M, Tachibana I, Takeda Y, He P, Minami S, et al. (2009) Tetraspanin
CD9 negatively regulates lipopolysaccharide-induced macrophage activation
and lung inflammation. J Immunol 182: 6485–6493.
40. Sohn MH, Kang MJ, Matsuura H, Bhandari V, Chen NY, et al. (2010) The
chitinase-like proteins breast regression protein-39 and YKL-40 regulate
hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 182: 918–928.
41. Agapov E, Battaile JT, Tidwell R, Hachem R, Patterson GA, et al. (2009)
Macrophage chitinase 1 stratifies chronic obstructive lung disease. Am J Respir
Cell Mol Biol 41: 379–384.
42. Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME (2005)
The eotaxin chemokines and CCR3 are fundamental regulators of allergen-
induced pulmonary eosinophilia. Journal of Immunology 175: 5341–5350.
43. Serra-Pages C, Medley QG, Tang M, Hart A, Streuli M (1998) Liprins, a family
of LAR transmembrane protein-tyrosine phosphatase-interacting proteins.
Journal of Biological Chemistry 273: 15611–15620.
44. Glavan BJ, Holden TD, Goss CH, Black RA, Neff MJ, et al. (2011) Genetic
Variation inthe FAS Geneand Associations with Acute Lung Injury. AmJRespir
Crit Care Med 83: 356–363.
45. Christie JD, Ma SF, Aplenc R, Li M, Lanken PN, et al. (2008) Variation in the
myosin light chain kinase gene is associated with development of acute lung
injury after major trauma. Crit Care Med 36: 2794–2800.
46. Zurner M, Schoch S (2009) The mouse and human Liprin-alpha family of
scaffolding proteins: genomic organization, expression profiling and regulation
by alternative splicing. Genomics 93: 243–253.
47. Asperti C, Astro V, Totaro A, Paris S, de Curtis I (2009) Liprin-alpha1 promotes
cell spreading on the extracellular matrix by affecting the distribution of
activated integrins. Journal of Cell Science 122: 3225–3232.
48. Asperti C, Pettinato E, de Curtis I (2010) Liprin-alpha1 affects the distribution of
low-affinity beta1 integrins and stabilizes their permanence at the cell surface.
Exp Cell Res 316: 915–926.
49. Reutershan J, Ley K (2004) Bench-to-bedside review: acute respiratory distress
syndrome - how neutrophils migrate into the lung. Crit Care 8: 453–461.
50. Crosby LM, Waters CM (2010) Epithelial repair mechanisms in the lung.
Am J Physiol Lung Cell Mol Physiol 298: L715–731.
51. Moreira-Teixeira L, Resende M, Coffre M, Devergne O, Herbeuval JP, et al.
(2011) Proinflammatory environment dictates the IL-17-producing capacity of
human invariant NKT cells. J Immunol 186: 5758–5765.
52. Crome SQ, Clive B, Wang AY, Kang CY, Chow V, et al. (2010) Inflammatory
effects of ex vivo human Th17 cells are suppressed by regulatory T cells.
J Immunol 185: 3199–3208.
53. Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, et al. (2010)
Analysis of CD161 expression on human CD8+ T cells defines a distinct
functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 107:
3006–3011.
54. Lim JC, You Z, Kim G, Levine RL (2011) Methionine sulfoxide reductase A is a
stereospecific methionine oxidase. Proc Natl Acad Sci U S A 108: 10472–10477.
55. Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, et al. (2000)
TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by
linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 5:
649–658.
56. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, et al. (2009) Direct activation of
protein kinases by unanchored polyubiquitin chains. Nature 461: 114–119.
57. Gorovoy M, Neamu R, Niu J, Vogel S, Predescu D, et al. (2007) RhoGDI-1
modulation of the activity of monomeric RhoGTPase RhoA regulates
endothelial barrier function in mouse lungs. Circ Res 101: 50–58.
58. Matsuda M, Yamashita JK, Tsukita S, Furuse M (2010) abLIM3 is a novel
component of adherens junctions with actin-binding activity. Eur J Cell Biol 89:
807–816.
59. Min J-W, Lee J-H, Park C-S, Chang HS, Rhim TY, et al. (2005) Association of
eotaxin-2 gene polymorphisms with plasma eotaxin-2 concentration. Journal of
Human Genetics 50: 118–123.
60. Barnes KC (2005) Genetic determinants and ethnic disparities in sepsis-
associated acute lung injury. Proceedings of the American Thoracic Society 2:
195–201.
61. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2007) Optimal designs for two-
stage genome-wide association studies. Genetic Epidemiology 31: 776–788.
62. Calfee CS, Eisner MD, Ware LB, Thompson BT, Parsons PE, et al. (2007)
Trauma-associated lung injury differs clinically and biologically from acute lung
injury due to other clinical disorders. Critical Care Medicine 35: 2243–2250.
63. Adamzik M, Frey UH, Riemann K, Sixt S, Lehmann N, et al. (2008) Factor V
Leiden mutation is associated with improved 30-day survival in patients with
acute respiratory distress syndrome. Crit Care Med 36: 1776–1779.
64. Gong MN, Thompson BT, Williams PL, Zhou W, Wang MZ, et al. (2006)
Interleukin-10 polymorphism in position 21082 and acute respiratory distress
syndrome. Eur Respir J 27: 674–681.
65. Reiner AP, Wurfel MM, Lange LA, Carlson CS, Nord AS, et al. (2008)
Polymorphisms of the IL1-Receptor Antagonist Gene (IL1RN) Are Associated
With Multiple Markers of Systemic Inflammation. Arterioscler Thromb Vasc
Biol 28: 1407–1412.
66. Gong MN, Wei Z, Xu LL, Miller DP, Thompson BT, et al. (2004)
Polymorphism in the surfactant protein-B gene, gender, and the risk of direct
pulmonary injury and ARDS. Chest 125: 203–211.
67. Lin Z, Pearson C, Chinchilli V, Pietschmann SM, Luo J, et al. (2000)
Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B
Thr131Ile with ARDS. Clin Genet 58: 181–191.
68. Quasney MW, Waterer GW, Dahmer MK, Kron GK, Zhang Q, et al. (2004)
Association between surfactant protein B+1580 polymorphism and the risk of
respiratory failure in adults with community-acquired pneumonia. Crit Care
Med 32: 1115–1119.
69. Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, et al. (2008) Toll-like
receptor 1 polymorphisms affect innate immune responses and outcomes in
sepsis. Am J Respir Crit Care Med 178: 710–720.
70. Gong MN, Zhou W, Williams PL, Thompson BT, Pothier L, et al. (2005) -
308GA and TNFB polymorphisms in acute respiratory distress syndrome. Eur
Respir J 26: 382–389.
71. Zhai R, Gong MN, Zhou W, Thompson TB, Kraft P, et al. (2007) Genotypes
and haplotypes of the VEGF gene are associated with higher mortality and lower
VEGF plasma levels in patients with ARDS. Thorax 62: 718–722.
72. Medford AR, Keen LJ, Bidwell JL, Millar AB (2005) Vascular endothelial
growth factor gene polymorphism and acute respiratory distress syndrome.
Thorax 60: 244–248.
73. Marshall RP, Webb S, Hill MR, Humphries SE, Laurent GJ (2002) Genetic
polymorphisms associated with susceptibility and outcome in ARDS. Chest 121:
68S–69S.
74. Sutherland AM, Walley KR, Manocha S, Russell JA (2005) The association of
interleukin 6 haplotype clades with mortality in critically ill adults. Arch Intern
Med 165: 75–82.
GWAS Identifies PPFIA1 as Candidate ALI Risk Gene
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e2826875. Nonas SA, Finigan JH, Gao L, Garcia JG (2005) Functional genomic insights
into acute lung injury: role of ventilators and mechanical stress. Proc Am Thorac
Soc 2: 188–194.
76. Flores C, Ma SF, Maresso K, Wade MS, Villar J, et al. (2008) IL6 gene-wide
haplotype is associated with susceptibility to acute lung injury. Transl Res 152:
11–17.
77. Su L, Zhai R, Sheu CC, Gallagher DC, Gong MN, et al. (2009) Genetic variants
in the angiopoietin-2 gene are associated with increased risk of ARDS. Intensive
Care Med 35: 1024–1030.
78. Meyer NJ, Li M, Feng R, Bradfield J, Gallop R, et al. (2011) ANGPT2 Genetic
Variant is Associated with Trauma-Associated Acute Lung Injury and Altered
Plasma Angiopoietin-2 Isoform Ratio. Am J Respir Crit Care Med 183:
1344–1353.
79. Gong MN, Zhou W, Williams PL, Thompson BT, Pothier L, et al. (2007)
Polymorphisms in the mannose binding lectin-2 gene and acute respiratory
distress syndrome. Crit Care Med 35: 48–56.
80. Ip WK, Chan KH, Law HK, Tso GH, Kong EK, et al. (2005) Mannose-binding
lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis
191: 1697–1704.
81. Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F, Aspa J, Briones ML,
et al. (2008) Mannose-binding lectin and mannose-binding lectin-associated
serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults.
J Allergy Clin Immunol 122: 368–374, 374e361–362.
82. Arcaroli J, Sankoff J, Liu N, Allison DB, Maloney J, et al. (2008) Association
between urokinase haplotypes and outcome from infection-associated acute lung
injury. Intensive Care Med 34: 300–307.
83. Pino-Yanes M, Ma S-F, Sun X, Tejera P, Corrales A, et al. Interleukin-1
Receptor-associated Kinase 3 Gene Associates with Susceptibility to Acute Lung
Injury. Am J Respir Cell Mol Biol, 2010-0292OC.
84. Zhai R, Zhou W, Gong MN, Thompson BT, Su L, et al. (2007) Inhibitor
kappaB-alpha haplotype GTC is associated with susceptibility to acute
respiratory distress syndrome in Caucasians. Crit Care Med 35: 893–898.
85. Lagan AL, Quinlan GJ, Mumby S, Melley DD, Goldstraw P, et al. (2008)
Variation in iron homeostasis genes between patients with ARDS and healthy
control subjects. Chest 133: 1302–1311.
86. Reddy AJ, Christie JD, Aplenc R, Fuchs B, Lanken PN, et al. (2008) Association
of Human Nad(P)H:Quinone Oxidoreductase 1 (Nqo1) Polymorphism with
Development of Acute Lung Injury. J Cell Mol Med.
87. Gao L, Flores C, Fan-Ma S, Miller EJ, Moitra J, et al. (2007) Macrophage
migration inhibitory factor in acute lung injury: expression, biomarker, and
associations. Transl Res 150: 18–29.
88. Adamzik M, Frey U, Sixt S, Knemeyer L, Beiderlinden M, et al. (2007) ACE I/
D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS.
Eur Respir J 29: 482–488.
89. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, et al.
(2002) Angiotensin converting enzyme insertion/deletion polymorphism is
associated with susceptibility and outcome in acute respiratory distress
syndrome. Am J Respir Crit Care Med 166: 646–650.
90. Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, et al. (2006) Polymorphism of
the angiotensin-converting enzyme gene affects the outcome of acute respiratory
distress syndrome. Crit Care Med 34: 1001–1006.
91. Adamzik M, Frey UH, Rieman K, Sixt S, Beiderlinden M, et al. (2007)
Insertion/deletion polymorphism in the promoter of NFKB1 influences severity
but not mortality of acute respiratory distress syndrome. Intensive Care Med 33:
1199–1203.
92. Sapru A, Hansen H, Ajayi T, Brown R, Garcia O, et al. (2009) 4G/5G
polymorphism of plasminogen activator inhibitor-1 gene is associated with
mortality in intensive care unit patients with severe pneumonia. Anesthesiology
110: 1086–1091.
GWAS Identifies PPFIA1 as Candidate ALI Risk Gene
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e28268